Intravenous Branched-chain Amino Acid Administration for the Acute Treatment of Hepatic Encephalopathy: a Systematic Review and Meta-analysis

Overview

Journal J Intensive Care

Publisher Biomed Central

Date 2025 Jan 9

PMID 39780295

Authors

Shoji Yokobori

Tomoaki Yatabe

Yutaka Kondo

Yasuhiko Ajimi

Manabu Araki

Norio Chihara

Masao Nagayama

Tetsuya Samkamoto

Affiliations

Soon will be listed here.

Abstract

Background: Hepatic encephalopathy (HE) is a severe complication of acute hepatic failure requiring urgent critical care management. Branched-chain amino acids (BCAAs) such as leucine, isoleucine, and valine have been investigated as potential treatments to improve outcomes in patients with acute HE. However, the effectiveness of BCAA administration during the acute phase remains unclear. This study aimed to evaluate the effect of intravenous BCAA (IV-BCAA) treatment on clinical outcomes in patients with acute HE by systematically reviewing and analyzing randomized controlled trials (RCTs).

Methods: We conducted a comprehensive literature search of MEDLINE, the Cochrane Central Register of Controlled Trials, and Igaku Chuo Zasshi (ICHUSHI), a Japanese database for medical literature. We included RCTs involving adult patients with acute HE who received IV-BCAA or placebo during the acute phase after admission (< 7 days). Two reviewers independently screened the citations and extracted data. The primary "critical" outcomes were mortality from any cause and improvement in disturbance of consciousness. The secondary "important" outcome included the incidence of complications such as nausea and diarrhea. Risk ratios (RRs) were calculated using random effects models with inverse variance weighting.

Results: Among the 2073 screened records, four met the criteria for quantitative analysis. The analysis included 219 patients: 109 received IV-BCAA, and 110 received placebo. Improvement in the disturbance of consciousness and mortality were not significantly different between the two groups (RR, 1.26; 95% confidence interval [CI], 0.96-1.66; RR, 0.90; 95% CI 0.70-1.16, respectively). Following IV-BCAA administration, the absolute differences of improvement in the disturbance of consciousness and mortality were 118 more per 1000 (95% CI 18 fewer-300 more) and 55 fewer per 1000 (95% CI 165 fewer-88 more), respectively. No significant differences were observed in the incidence of nausea or diarrhea between the two groups.

Conclusions: Our meta-analysis demonstrates that all outcomes were not significantly different between IV-BCAA treatment and placebo for acute HE. Further RCTs are required to better understand IV-BCAA treatment potential in patients with HE.

References

Gluud L, Dam G, Les I, Marchesini G, Borre M, Aagaard N . Branched-chain amino acids for people with hepatic encephalopathy. Cochrane Database Syst Rev. 2017; 5:CD001939. PMC: 6481897. DOI: 10.1002/14651858.CD001939.pub4. View

Marrone G, Serra A, Miele L, Biolato M, Liguori A, Grieco A . Branched chain amino acids in hepatic encephalopathy and sarcopenia in liver cirrhosis: Evidence and uncertainties. World J Gastroenterol. 2023; 29(19):2905-2915. PMC: 10237095. DOI: 10.3748/wjg.v29.i19.2905. View

Ooi P, Gilmour S, Yap J, Mager D . Effects of branched chain amino acid supplementation on patient care outcomes in adults and children with liver cirrhosis: A systematic review. Clin Nutr ESPEN. 2018; 28:41-51. DOI: 10.1016/j.clnesp.2018.07.012. View

Marchesini G, Bianchi G, Merli M, Amodio P, Panella C, Loguercio C . Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology. 2003; 124(7):1792-801. DOI: 10.1016/s0016-5085(03)00323-8. View

Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen K . Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014; 60(2):715-35. DOI: 10.1002/hep.27210. View

Louissaint J, Deutsch-Link S, Tapper E . Changing Epidemiology of Cirrhosis and Hepatic Encephalopathy. Clin Gastroenterol Hepatol. 2022; 20(8S):S1-S8. PMC: 9531320. DOI: 10.1016/j.cgh.2022.04.036. View

Kawaguchi T, Taniguchi E, Sata M . Effects of oral branched-chain amino acids on hepatic encephalopathy and outcome in patients with liver cirrhosis. Nutr Clin Pract. 2013; 28(5):580-8. DOI: 10.1177/0884533613496432. View

Butterworth R . Hepatic Encephalopathy in Cirrhosis: Pathology and Pathophysiology. Drugs. 2019; 79(Suppl 1):17-21. PMC: 6416236. DOI: 10.1007/s40265-018-1017-0. View

Naylor C, ORourke K, Detsky A, Baker J . Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy. A meta-analysis. Gastroenterology. 1989; 97(4):1033-42. DOI: 10.1016/0016-5085(89)91517-5. View

10.

Nakaya Y, Okita K, Suzuki K, Moriwaki H, Kato A, Miwa Y . BCAA-enriched snack improves nutritional state of cirrhosis. Nutrition. 2007; 23(2):113-20. DOI: 10.1016/j.nut.2006.10.008. View

11.

. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. J Hepatol. 2014; 61(3):642-59. DOI: 10.1016/j.jhep.2014.05.042. View

12.

Les I, Doval E, Garcia-Martinez R, Planas M, Cardenas G, Gomez P . Effects of branched-chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. Am J Gastroenterol. 2011; 106(6):1081-8. DOI: 10.1038/ajg.2011.9. View

13.

Gluud L, Dam G, Borre M, Les I, Cordoba J, Marchesini G . Oral branched-chain amino acids have a beneficial effect on manifestations of hepatic encephalopathy in a systematic review with meta-analyses of randomized controlled trials. J Nutr. 2013; 143(8):1263-8. DOI: 10.3945/jn.113.174375. View

14.

Malaguarnera M, Risino C, Cammalleri L, Malaguarnera L, Astuto M, Vecchio I . Branched chain amino acids supplemented with L-acetylcarnitine versus BCAA treatment in hepatic coma: a randomized and controlled double blind study. Eur J Gastroenterol Hepatol. 2009; 21(7):762-70. DOI: 10.1097/MEG.0b013e328309c791. View

15.

Wahren J, Denis J, Desurmont P, Eriksson L, Escoffier J, GAUTHIER A . Is intravenous administration of branched chain amino acids effective in the treatment of hepatic encephalopathy? A multicenter study. Hepatology. 1983; 3(4):475-80. DOI: 10.1002/hep.1840030402. View

16.

Marchesini G, Dioguardi F, Bianchi G, Zoli M, Bellati G, Roffi L . Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy. A randomized double-blind casein-controlled trial. The Italian Multicenter Study Group. J Hepatol. 1990; 11(1):92-101. DOI: 10.1016/0168-8278(90)90278-y. View

17.

Dioguardi F, Brigatti M, DellOca M, Ferrario E, Abbiati R . Effects of chronic oral branched-chain amino acid supplementation in a subpopulation of cirrhotics. Clin Physiol Biochem. 1990; 8(2):101-7. View

18.

Fallahzadeh M, Rahimi R . Hepatic Encephalopathy: Current and Emerging Treatment Modalities. Clin Gastroenterol Hepatol. 2022; 20(8S):S9-S19. DOI: 10.1016/j.cgh.2022.04.034. View

19.

Mehtani R, Premkumar M, Garg S, Kajal K, Kulkarni A, Duseja A . Intravenous BCAA Infusion Does Not Lead to a Sustained Recovery From Overt HE in ACLF - An Open Label Randomized Clinical Trial. J Clin Exp Hepatol. 2023; 13(6):977-988. PMC: 10643498. DOI: 10.1016/j.jceh.2023.05.015. View

20.

Bianchi G, Marchesini G, Zoli M, Abbiati R, Ferrario E, Fabbri A . Oral BCAA supplementation in cirrhosis with chronic encephalopathy: effects on prolactin and estradiol levels. Hepatogastroenterology. 1992; 39(5):443-6. View